

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 January 2010 (14.01.2010)

(10) International Publication Number  
**WO 2010/005643 A1**

(51) International Patent Classification:  
*C07D 471/08* (2006.01)

(21) International Application Number:  
PCT/US2009/045478

(22) International Filing Date:  
28 May 2009 (28.05.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/134,653 10 July 2008 (10.07.2008) US  
61/134,881 14 July 2008 (14.07.2008) US  
61/137,947 4 August 2008 (04.08.2008) US  
61/189,154 14 August 2008 (14.08.2008) US  
61/157,354 4 March 2009 (04.03.2009) US

(71) Applicant (for all designated States except BB, US):  
**TEVA PHARMACEUTICAL INDUSTRIES LTD.**  
[IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petah Tiq-  
va (IL).

(71) Applicant (for BB only): **TEVA PHARMACEUTI-  
CALS USA, INC.** [US/US]; 1090 Horsham Road, P.o.  
Box 1090, North Wales, PA 19454-1090 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIFSHITZ-  
LIRON, Revital** [IL/IL]; Uriel-ofek Street 8/28, Herzlia  
(IL). **SHABAT, Shalom** [IL/IL]; Marganit 3, Yavne (IL).  
**TOMER, Sharon** [IL/IL]; 7 Yochanan Horkanus Street,  
Tel Aviv (IL). **RAIZI, Yuriy** [IL/IL]; 34 Rishon Le Zion

Str., 42374 Natanya (IL). **GILBOA, Eyal** [IL/IL]; Haza-  
mir 2/4, Qiryat Ono (IL). **PANDEY, Pramod, Kumar**  
[IN/IN]; B-223 (ground Floor), Green Field Colony,  
Faridabad (haryana) (IN).

(74) Agents: **MORADIAN, Payam** et al.; Kenyon & Kenyon  
Llp, One Broadway, New York, NY 10004-1050 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,  
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,  
SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,  
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),  
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



**WO 2010/005643 A1**

(54) Title: PROCESSES FOR PURIFYING VARENICLINE L-TARTRATE SALT AND PREPARING CRYSTALLINE FORMS OF VARENICLINE L-TARTRATE SALT

(57) Abstract: Processes for purifying Varenicline base or the L-tartrate salt thereof and for preparing Varenicline L-tartrate crystalline forms A and B are provided.

PROCESSES FOR PURIFYING VARENICLINE L-TARTRATE SALT AND  
PREPARING CRYSTALLINE FORMS OF VARENICLINE L-TARTRATE SALT

RELATED APPLICATIONS


[0001] This application claims benefit of U.S. Provisional Patent Applications Nos. 61/157,354, filed March 4, 2009, 61/189,154, filed August 14, 2008, 61/137,947, filed August 4, 2008, 61/134,881, filed July 14, 2008, and 61/134,653, filed July 10, 2008, the contents of which are incorporated herein in their entirety by reference.

FIELD OF INVENTION

[0002] The present invention is directed to processes for purifying Varenicline base and Varenicline L-tartrate salt and preparing crystalline forms A and B of Varenicline L-tartrate salt (VRN L-tartrate).

BACKGROUND OF THE INVENTION

[0003] Varenicline tartrate salt, 7,8,9,10-tetrahydro-6,10-methano-6*H*-pyrazino[2,3-*h*][3]benzazepine, (2*R*,3*R*)-2,3-dihydroxybutanedioate (1:1) has the following formula:



[0004] Varenicline tartrate is marketed by Pfizer under the trade name of CHANTIX™ as a partial agonist selective for certain subtypes of nicotinic receptors and indicated for smoking cessation.

[0005] Varenicline base and various salts thereof are described in the U.S. Patent No. 6,410,550, EP 1044189, EP 1659114, and EP1866308.

[0006] Varenicline L-tartrate and its crystalline forms A, characterized by XRPD peaks at 6.1, 12.2, 13.0, 14.7, 16.8, 19.4, 21.9, 24.6; B, characterized by XRPD peaks at 5.9, 12.8, 14.4, 15.3, 16.9, 17.2, 21.8, 23.8, 25.1; and C, characterized by XRPD peaks at 5.9, 11.8, 16.5, 21.2, 23.1, 23.8, 26.5 are described in the U.S. Patents Nos. 6,890,927 and 7,265,119.

[0007] WO 2008/060487 describes crystalline forms of Varenicline base and intermediates thereof.

[0008] U.S. Patent No. 6,897,310 describes a nitro intermediate and U.S. Patent No. 6,951,938 describes an amino intermediate of Varenicline.

[0009] U.S. Patent Application Publication No. 2007/0224690 describes Varenicline having 0 to 500 ppm of several impurities.

[00010] Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, like Varenicline (VRN) L-tartrate, may give rise to a variety of crystalline forms having distinct crystal structures and physical properties. The difference in the physical properties of different crystalline forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous physical properties compared to other crystalline forms of the same compound or complex.

[00011] The present invention relates to the solid state physical properties of Varenicline L-tartrate. These properties can be influenced by controlling the conditions under which Varenicline L-tartrate is obtained in solid form. Solid state physical properties include, for example, the flow-ability of the milled solid. Flow-ability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch, or tribasic calcium phosphate.

[00012] Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid. The rate of dissolution of an active

ingredient in a patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream. The rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments. The solid state form of a compound may also affect its behavior on compaction and its storage stability.

[00013] The discovery of new polymorphic forms of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic.

[00014] There is a need in the art for new processes for preparing polymorphic forms of Varenicline L-tartrate and for additional processes for purifying Varenicline L-tartrate.

#### SUMMARY OF THE INVENTION

[00015] In one embodiment, the present invention provides a process for purifying Varenicline base or L-tartrate salt thereof, comprising filtering an aqueous solution, ethanol-water solution, methanolic solution, or mixtures thereof of Varenicline base or L-tartrate salt thereof in the presence of activated carbon, wherein filtering is performed using a filter aid.

[00016] Optionally, when the Varenicline used in the process of the present invention is Varenicline L-tartrate salt, spray drying is further performed on the obtained salt.

[00017] In a preferred embodiment, the Varenicline L-tartrate subjected to filtration described in the present invention is prepared by a process comprising: a) combining a solution of Varenicline base in methanol with L-tartaric acid to obtain a compound of Varenicline L-tartrate, and b) drying the obtained compound to obtain Varenicline L-tartrate. Preferably, the Varenicline L-tartrate obtained is in an amorphous form.

[00018] Optionally, the filtrated Varenicline base obtained in the process of present invention is combined with methanolic L-tartaric acid to obtain Varenicline L-tartrate.

[00019] In one embodiment, the present invention provides a process for preparing Varenicline L-tartrate crystalline form A, comprising dissolving Varenicline L-tartrate in water, and precipitating Varenicline L-tartrate form A by adding the aqueous solution of Varenicline L-tartrate to an anti-solvent.

[00020] In another embodiment, the present invention provides a process for preparing Varenicline L-tartrate crystalline form B, comprising dissolving Varenicline L-tartrate in water, and precipitating Varenicline L-tartrate form B by adding an anti-solvent to the aqueous solution of Varenicline L-tartrate, wherein the water used is not more than 1.5 percent of the total volume.

[00021] In yet another embodiment, the present application provides a process for preparing Varenicline L-tartrate crystalline form B, comprising combining Varenicline base, L-tartaric acid, and an ethanol-water solution to precipitate Varenicline L-tartrate crystalline form B.

#### DETAILED DESCRIPTION OF THE INVENTION

[00022] The present invention relates to purification processes of Varenicline base and Varenicline L-tartrate salt using filtration and activated carbon.

[00023] Filtration can be performed using filter aids. The filter aids and other reagents used in the process of the present application are commercially available and suitable for industrial scale production.

[00024] As used herein, the term "filter aids" refers to inert porous solids, such as, e.g., those made primarily of silica or wood cellulose, which are used to aid filtration. Examples of filter aids that may be used in the present invention include tonsil beds, hyflow beds, celite functional filters, and macro-cel functional filters. A tonsil bed is typically an acid-activated calcium Bentonite (an absorbent aluminum phyllosilicate, generally impure clay consisting mostly of montmorillonite). A sinter bed is typically a finely perforated glass filter in which a filter aid, such as tonsil bed, may be adapted.

[00025] The present invention also relates to processes for preparing crystalline forms A and B of Varenicline L-tartrate salt.

[00026] In one embodiment, the present invention provides a process for purifying Varenicline base or L-tartrate salt thereof, comprising filtering an aqueous solution, ethanol-water solution, methanolic solution or mixtures thereof of Varenicline base or L-tartrate salt thereof in the presence of activated carbon, wherein filtering is performed using a filter aid

[00027] The filter aid used in the purification process described above is preferably selected from a group consisting of tonsil beds, hyflow beds, celite functional filters, and macro-cel functional filters. More preferably, the filter aid is a tonsil bed.

[00028] Preferably, the filter aid is used with vacuum filtration under reduced pressure. More preferably, the reduced pressure is between about 10 mbar to about 100 mbar. Most preferably it is about 30 mbar.

[00029] The Varenicline L-tartrate salt obtained according to the above process is obtained with purity greater than about 99.6 percent by area HPLC. Preferably, it is obtained with purity greater than about 99.9 percent. Most preferably it is obtained with a purity of about 100 percent.

[00030] When the Varenicline used in the above process is Varenicline L-tartrate salt, spray drying is preferably further performed on the obtained salt.

[00031] The term "spray drying" broadly refers to processes involving breaking up liquid mixtures into small droplets (atomization), and rapidly removing solvent from the mixture. In a typical spray drying apparatus, there is a strong driving force for evaporation of solvent from the droplets, which may be provided by providing a drying gas. Spray drying processes and equipment are described in Perry's Chemical Engineer's Handbook, pgs. 20-54 to 20-57 (Sixth Edition 1984), which is incorporated herein by reference.

[00032] By way of non-limiting example only, the typical spray drying apparatus comprises a drying chamber, atomizing means for atomizing a solvent-containing feed into the drying chamber, a source of drying gas that flows into the drying chamber to remove solvent from the atomized-solvent-containing feed, an outlet for the products of drying, and product collection means located downstream of

the drying chamber. Examples of such apparatuses include Niro Models PSD-1, PSD-2 and PSD-4 (Niro A/S, Soeborg, Denmark), and BUCHI Model B-290 mini spray dryer.

[00033] As used herein, an "inlet temperature" is the temperature at which the drying gas enters the spray dryer; an "outlet temperature" is the temperature at which the gas exits the spray dryer.

[00034] Inlet or outlet temperatures may be varied, if necessary, depending on the equipment, gas, or other experimental parameters. For example, it is known that the outlet temperature may depend on parameters such as aspirator rate, air humidity, inlet temperature, spray air flow, feed rate, concentration, or a combination thereof.

[00035] When spray drying is performed in the process of the present invention, the inlet temperature is typically between about 180°C to about 230°C, and, preferably, about 190°C to about 220°C. More preferably, the inlet temperature is about 213°C to about 220°C. The outlet temperature is typically about 105°C to about 130°C, and, preferably, about 113°C to 120°C. More preferably the outlet temperature is about 117°C to about 119°C.

[00036] Typically, the product collection means includes a cyclone connected to the drying apparatus. In the cyclone, the particles produced during spray drying are separated from the drying gas and evaporated solvent, allowing the particles to be collected. A filter may also be used to separate and collect the particles produced by spray drying. Spray-drying may be performed in a conventional manner in the processes of the present invention (*see, e.g.*, Remington: The Science and Practice of Pharmacy, 19th ed., vol. II, pg. 1627, herein incorporated by reference). The drying gas used in the invention may be any suitable gas, although inert gases such as nitrogen, nitrogen-enriched air, and argon are preferred. Nitrogen gas or air is a particularly preferred drying gas for use in the process of the invention. The amorphous Varenicline L-tartrate product produced by spray-drying may be recovered by techniques commonly used in the art, such as by using a cyclone or a filter.

[00037] Preferably, methanolic L-tartaric acid is added when an aqueous solution of Varenicline base is filtered.

[00038] In a preferred embodiment, a powdery compound of Varenicline L-tartrate is first obtained by addition of L-tartaric acid to a solution of Varenicline base in methanol, the wet material is dried, and dissolved in water in the presence of activated carbon (CXV). The resulting mixture is then filtered using a sinter and tonsil bed under reduced pressure, and the solvent is removed by spray-drying to give purified Varenicline L-tartrate in an amorphous form. Preferably, the Varenicline L-tartrate obtained according to the above preferred process is obtained with a purity of about 100 percent by area HPLC.

[00039] In one specific embodiment, the aqueous solution of Varenicline base used in the above process also contains methanol. Typically, L-methanolic tartaric acid is further added to obtain pure Varenicline L-tartrate salt.

[00040] In another specific embodiment, activated carbon (CXV) is added to Varenicline base in methanol, the obtained mixture is filtered under reduced pressure using a sinter and tonsil bed, a methanolic solution of L-tartaric acid is added to the filtered Varenicline base solution, and a precipitate of Varenicline L-tartrate is obtained.

[00041] In one embodiment, the present invention provides a process for preparing Varenicline L-tartrate crystalline form A, comprising dissolving Varenicline L-tartrate in water, and precipitating Varenicline L-tartrate form A by adding the aqueous solution of Varenicline L-tartrate to an anti-solvent.

[00042] Preferably, when the aqueous solution of Varenicline L-tartrate is added to the anti-solvent, it is added drop-wise.

[00043] Preferably, the aqueous solution of Varenicline L-tartrate is added at a temperature of about 50°C to about 80°C. More preferably, it is added at a temperature of about 70°C.

[00044] The volume ratio between the anti-solvent and the water used in the process described above is between about 1:15 to about 1:35 (v/v) of water:anti-solvent. More preferably, the ratio is between about 1:20 to about 1:35. Most preferably, it is about 1:33 (v/v).

[00045] In another embodiment, the present invention provides a process for preparing Varenicline L-tartrate crystalline form B, comprising dissolving Varenicline L-tartrate in water, and precipitating Varenicline L-tartrate form B by adding an



anti-solvent to the aqueous solution of Varenicline L-tartrate, wherein the water used is not more than 1.5 percent of the total volume.

[00046] Preferably, the water is used at 1.4 percent, more preferably at 1.3 percent of the total volume.

[00047] The volume ratio between the anti-solvent and the water used in the process described above is between about 1:5 to about 1:10 (v/v) of water:anti-solvent. More preferably, the ratio is between about 1:8 to about 1:10. Most preferably, it is about 1:9 (v/v).

[00048] The anti-solvent used in any of the processes described above is selected from a group consisting of C<sub>1</sub>-C<sub>4</sub> alcohols, tetrahydrofuran (THF), and acetonitrile. Preferably, the anti-solvent is selected from a group consisting of ethanol or isopropanol, THF and acetonitrile. Most preferably, the anti-solvent is ethanol.

[00049] In yet another embodiment, the present application provides a process for preparing Varenicline L-tartrate crystalline form B, comprising combining Varenicline base, L-tartaric acid, and ethanol-water solution to precipitate Varenicline L-tartrate crystalline form B.

[00050] The ethanol-water solution in the process described above is at a volume ratio of about 90 percent:10 percent (9:1) to about 98 percent:2 percent (49:1) of ethanol:water (v/v). Preferably, the ratio is about 92 percent:8 percent (11.5:1) (v/v) to about 96 percent:4 percent (24:1) (v/v), and more preferably, it is about 95 percent:5 percent (19:1) (v/v).

[00051] The reaction mixture described above contains Varenicline base and ethanol-water at a ratio of about 10:1 to about 5:1 of ethanol-water:Varenicline base (v/w). Preferably, the ratio is about 9:1 to about 7:1 (v/w), and more preferably the ratio is about 7.5:1 (v/w).

[00052] Optionally, Varenicline base is reacted with activated carbon (CVX) prior to its addition to the reaction mixture.

[00053] Varenicline L-tartrate form B used in any of the above processes can be obtained according to any method known in the art, for example in U.S. Patents Nos. 6,890,927 and 7,265,119, incorporated herein by reference, wherein L-tartaric acid in methanol was combined with Varenicline base in methanol, or according to examples 3 and 10 of the present application.

[00054] Varenicline base used in any of the above processes may be obtained according to any method known in the art, for example in U.S. Patent No. 6,410,550

incorporated herein by reference, wherein 1-(5,8,14-Triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,9-pentaene)-2,2,2-trifluoro-ethanone in methanol is reacted with a base, e.g., alkali metal, alkaline earth metal carbonates or hydroxides, and then heated, or according to the first part of example 3 of the present application.

[00055] Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The disclosures of the references referred to in this patent application are incorporated herein by reference. The invention is further defined by reference to the following examples describing in detail the process and compositions of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.

### EXAMPLES

#### Experimental methodology:

<u>HPLC</u>													
<b>Column &amp; packing</b>	Chromatopak C18 150, 4.6mm, 5 $\mu$ P.N 1546511												
<b>Eluent</b>	A – 75% - 0.02 M NH <sub>4</sub> H <sub>2</sub> PO <sub>4</sub> adjusted to pH=6.0 with NH <sub>4</sub> OH 25% - MeOH B – 20% - 0.02 M NH <sub>4</sub> H <sub>2</sub> PO <sub>4</sub> adjusted to pH=6.0 with NH <sub>4</sub> OH 80% - MeOH												
<b>Gradient</b>	<table style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th>A</th> <th>B</th> </tr> </thead> <tbody> <tr> <td><b>0</b></td> <td>100</td> <td>0</td> </tr> <tr> <td><b>5 min</b></td> <td>100</td> <td>0</td> </tr> <tr> <td><b>30 min</b></td> <td>0</td> <td>100</td> </tr> </tbody> </table>		A	B	<b>0</b>	100	0	<b>5 min</b>	100	0	<b>30 min</b>	0	100
	A	B											
<b>0</b>	100	0											
<b>5 min</b>	100	0											
<b>30 min</b>	0	100											
<b>Stop time:</b>	30 min												
<b>Flow:</b>	1.0 ml/min												
<b>Detector:</b>	210 nm.												
<b>Injection volume:</b>	10 $\mu$ l.												
<b>Diluent</b>	Eluent A												
<b>Column temperature</b>	25°C												

Sample solution preparation:

[00056] Weigh accurately about 20 mg of Varenicline Tartrate sample into a 20 ml volumetric flask, dissolve, and dilute to volume with diluent. Dilute 5 ml into a 10 ml volumetric flask with diluent.

Method:

[00057] Inject sample solutions continuing the chromatogram up to the end of gradient. Determine the area of each impurity using suitable integrator.

Calculations:

[00058] Any impurity in a sample is calculated as follows:

$$\% \text{ Impurity in sample} = \frac{\text{area impurity in sample}}{\sum \text{Areas of all peaks}} \times 100$$

Water content-

[00059] Water content was determined by Karl Fisher (KF) analysis using Mettler Toledo DL 38 Karl Fisher Titrator.

Example 1-Purification of Varenicline L-Tartrate:Method 1:

[00060] 3.15 g of L-Tartaric acid was dissolved in 34 ml of water. 4 g of Varenicline base was added at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 5 minutes to get a clear solution. To the clear solution, 0.8 g activated carbon (CXV) was added, and stirred at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 30 minutes. The mixture was vacuum filtered under reduced pressure with a Sinter and tonsil. Then the solution was spray dried to obtain amorphous Varenicline L-Tartrate. The nitrogen gas was at an inlet temperature of  $220^{\circ}$  to  $190^{\circ}\text{C}$ . The evaporated solvent and nitrogen left the spray dryer at a temperature of  $113^{\circ}$  to  $120^{\circ}\text{C}$ .

The impurity profile obtained by HPLC analysis of Method 1 is provided in table 1

Table 1:

Description	Impurity profile by HPLC (% area) RT/RRT									
	0.97	3.07/ 3.86	3.72/ 5.39	4.53	5.32	5.90/ 7.71	10.27 / 9.77	10.8 6	16.1 7	21.8 / 23.8
	0.18	0.82	1.00	1.22	1.43	1.59	2.76	2.92	4.35	5.86
VRN Base	ND	0.11	98.29	0.02	0.08	0.57	0.05	0.38	0.22	0.29
VRN Tartrate	ND	ND	99.95	ND	ND	ND	ND	ND	ND	0.05

Method 2:

[00061]

A. 20 g of Varenicline base were dissolved in 150 ml of methanol, and stirred for 20 minutes. To the obtained solution, 15.7 g of L-tartaric acid dissolved in 150 ml methanol was added at 25° ± 5°C for 30 to 40 minutes to precipitate Varenicline L-Tartrate. The mixture was stirred at 25° ± 5°C for 2 to 20 hours, filtered, and washed with 70 ml methanol to get a powdery compound. The wet material was dried under vacuum at T ≤ 50°C.

B. 5 g of Varenicline L-Tartrate were dissolved in 40 ml water at about 25° ± 5°C. To the clear solution, 1 g activated carbon (CXV) was added, and stirred at 25° ± 5°C for 30 minutes. The mixture was vacuum filtered under reduced pressure with a Sinter and tonsil. Then, the solution was spray dried to obtain amorphous Varenicline L-Tartrate. The nitrogen gas was at an inlet temperature of 220° to 213°C. The evaporated solvent and nitrogen left the spray dryer at a temperature of 117° to 119°C.

The impurity profile obtained by HPLC analysis of Method 2 is provided in table 2

Table 2:

Impurity profile by HPLC (% area) RT/RRT	

	4.44	4.7	6.0	22.3
	1.00	1.4	1.44	5.36
<b>VRN Tartrate</b>	99.65	ND	0.12	0.2
<b>After spray-dryer</b>	100	ND	ND	ND

Example 2-Purification of Varenicline L-Tartrate:

Method 3:

[00062] 25 g of Varenicline base were dissolved in 150 ml methanol. To the clear solution activated carbon (CXV) was added, and the obtained mixture was stirred at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 30 minutes. The mixture was vacuum filtered under reduced pressure with a Sinter and tonsil bed. The Varenicline base solution was added to a methanolic solution of L-Tartaric acid (19.7 g) (dissolved in 7.5 volume of methanol relative to Varenicline base) at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 10 to 40 minutes to precipitate Varenicline L-Tartrate. The mixture was stirred at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 2 to 20 hours, filtered, and washed with 70 ml of methanol to get a powdery creamy solid. The wet material was dried under vacuum at  $T_j = 50^{\circ}\text{C}$ .

Method 4:

[00063] 25 g of Varenicline base was dissolved in 150 ml methanol and 6 ml water. To the clear solution activated carbon (CXV) was added, and the obtained mixture was stirred at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 30 minutes. The mixture was vacuum filtered under reduced pressure with a Sinter and tonsil bed. The Varenicline base solution was added to a methanolic solution of L-Tartaric acid (19.7 g) (dissolved in 7.5 volume of methanol relative to Varenicline base) at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 10 to 40 minutes to precipitate Varenicline L-Tartrate. The mixture was stirred at  $25^{\circ} \pm 5^{\circ}\text{C}$  for 2 to 20 hours, filtered, and washed with 70 ml of methanol to get a powdery white to off-white solid. The wet material was dried under vacuum at  $T_j = 50^{\circ}\text{C}$ .

The impurity profile obtained by HPLC analysis of Methods 3 and 4 is provided in Table 3.

Table 3:

Description	Yield%	Impurity profile by HPLC (% area) RRT									ASSAY %
		0.82q	1.00	1.22	1.43	1.59	2.76	2.92	4.35	5.86	
VRN Base	NA	0.11	98.29	0.02	0.08	0.57	0.05	0.38	0.22	0.29	90.3%
Method 3- Crystallization from Methanol	86%	0.03	99.62	ND	ND	0.05	0.08	ND	ND	0.23	98.36
Method 4- Crystallization from Methanol and water (4% v/v vs. Methanol)	60%	ND	99.91	ND	ND	0.03	0.02	ND	ND	0.03	101.9%

Example 3: Reference example: Example 4 of EP 1866308: Preparation of Varenicline L-tartrate Form B

[00064] A clean, dry 4 neck round bottom flask equipped with mechanical stirrer and thermo pocket was charged with toluene (119.0 ml), 1-(5,8,14-triazatetracyclo [10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,9-pentane)-2,2,2-trifluoroethanone (17.0 gm) at 25-30°C, which was treated with 2N aqueous solution of sodium hydroxide (86.03 ml) with stirring. The mixture was warmed to 30° to 35°C for 2 hours, and progress of the reaction was monitored by HPLC/TLC (MDC: MeOH 9:1). After completion of the reaction, toluene (170 ml) was added to the reaction mixture, and stirred for 20 minutes. The layers were separated, and the aqueous layer was extracted with toluene (2X85ml). Combined organic layer was distilled to remain in residue up to 5 volumes. To the above solution, methanol (255 ml) was charged and azeotropically distilled under vacuum up to 5 volumes (85ml). Methanol (170 ml) was charged, and again azeotropically distilled under vacuum up to 5 volumes (85ml). Methanol (305 ml) was added in the remaining methanolic solution, which was further treated with activated carbon (1.7gm) for 1 hour at 25° to 30°C. Filtered the solution through celite bed and transferred to an addition funnel.

[00065] In a separate clean and dry 4-neck round bottom flask, L-(+)-Tartaric acid (9.14 gm) was dissolved in methanol (221 ml) at 25° to 30°C. To this above

methanolic solution, Varenicline base was added drop wise in 20 to 30 minutes through an addition funnel. The resulting precipitate was stirred for 1 hour, filtered, and washed with methanol (34 ml) to afford the product i.e.

5,8,14Triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene Tartrate salt (Varenicline L-Tartrate). (Yield 15.7 gm, HPLC Purity NLT -99.5 percent).

#### Preparation of Varenicline L-tartrate Form A

##### Example 4:

[00066] Varenicline L-tartrate Form B (0.15g, obtained in example 3) was dissolved in water (3 vol. 0.45 ml) at 70°C. The solution was added drop-wise into Isopropanol (100 vol, 15 ml), and precipitation occurred. The slurry was stirred 48 hours, filtered and dried in 55°C vacuum oven. A PXRD analysis confirmed the product was Varenicline L-tartrate Form A.

##### Example 5:

[00067] Varenicline L-tartrate Form B (0.15g, obtained in example 3) was dissolved in water (3 vol, 0.45 ml) at 70°C the solution was added drop-wise into Ethanol (100 vol,15 ml) and precipitation occurred. The slurry was stirred 48 hours, filtered and dried in 55°C vacuum oven. A PXRD analysis confirmed the product was Varenicline L-tartrate Form A.

#### Preparation of Varenicline L-tartrate Form B

##### Example 6:

[00068] Varenicline L-tartrate Form B (0.15g, obtained in example 3) was dissolved in water (10 vol,1.5 ml at 70°C Acetonitrile (66 vol,10 ml) was added, and precipitation occurred. The slurry was cooled to room temperature, stirred 16 hours, filtered, and dried in 55°C vacuum oven. A PXRD analysis confirmed the product was Varenicline L-tartrate Form B.

##### Example 7:

[00069] Varenicline L-tartrate Form B (0.15g, obtained in example 3) was dissolved in water (10 vol, 1.5 ml) at 70°C. Ethanol (93 vol, 14 ml) was added, and precipitation occurred. The slurry was cooled to room temperature, stirred 16 hours,

filtered, and dried in 55°C vacuum oven. A PXRD analysis confirmed the product was Varenicline L-tartrate Form B.

Example 8:

[00070] Varenicline L-tartrate Form B (0.15g, obtained in example 3) was dissolved in water (10 vol, 1.5 ml) at 70°C. Isopropanol (93 vol, 14 ml) was added, and precipitation occurred. The slurry was cooled to room temperature, stirred 16 hours, filtered, and dried in 55°C vacuum oven. A PXRD analysis confirmed the product was Varenicline L-tartrate Form B.

Example 9:

[00071] Varenicline L-tartrate Form B (0.15g, obtained in example 3) was dissolved in water (10 vol, 1.5 ml) at 70°C. Tetrahydrofuran (80 vol, 12 ml) was added, and precipitation occurred. The slurry was cooled to room temperature, stirred 16 hours, filtered, and dried in 55°C vacuum oven. A PXRD analysis confirmed the product was Varenicline L-tartrate Form B.

Example 10:

[00072] 120 g of Varenicline base were dissolved in 900 ml Ethanol 95 percent (5 percent water). To the clear solution activated carbon (CXV) was added, and the obtained mixture was stirred at  $25 \pm 5^\circ\text{C}$  for 30 minutes. The mixture was filtered under reduced pressure with Sinter, and washed with Ethanol 95 percent (5 percent water).

[00073] The Varenicline base solution was added to a solution of L-Tartaric acid (94.44g) in Ethanol 95 percent (5 percent water) 900 ml (dissolved in 7.5 volume of Ethanol 95 percent (5 percent water) relate to Varenicline base) at  $25 \pm 5^\circ\text{C}$  for 10 to 40 minutes to get a precipitation of Varenicline L-Tartarate. The mixture was stirred at  $25 \pm 5^\circ\text{C}$  for 2 to 20 hours, filtered, and washed with 240 ml of Ethanol 95 percent (5 percent water) to get a powdery white to off-white solid. The wet material was dried under vacuum at  $T_j = 50^\circ\text{C}$ , to obtain Form B.

Impurity profile by HPLC (% area)		Ash	KF	L-Tartaric Acid	ASSAY %
RRT					
7.7	17.4				



1.0	2.27			(%)	
99.95	0.05	0.02	0.36	41.6	101.9

We claim:

1. A process for purifying Varenicline base or L-tartrate salt thereof, comprising filtering an aqueous solution, ethanol-water solution, methanolic solution, or mixtures thereof of Varenicline base or L tartrate-salt thereof in the presence of activated carbon, wherein the filtering comprises the use of a filter aid.

2. The process of claim 1, wherein the filter aid is selected from a group consisting of a tonsil bed, hyflow bed, celite functional filter, and macro-cel functional filter.

3. The process of claim 2, wherein the filter aid is a tonsil bed.

4. The process of any of claims 1 to 3, wherein the filtering with the filter aid is vacuum filtration at a pressure of about 10 mbar to about 100 mbar.

5. The process of claim 4, wherein the pressure is about 30 mbar.

6. The process of any of claims 1 to 5, wherein the obtained Varenicline L-tartrate salt has a purity greater than about 99.6 percent by area HPLC.

7. The process of any of claims 6, wherein the obtained Varenicline L-tartrate salt has a purity greater than about 99.9 percent by area HPLC.

8. The process of claim 7, wherein the obtained Varenicline L-tartrate salt has a purity of about 100 percent by area HPLC.

9. The process of claim 1, wherein the resulting filtered solution of Varenicline L-tartrate salt is spray dried.

10. The process of claim 9, wherein the Varenicline L-tartrate salt is spray dried at an inlet temperature of about 180°C to about 230°C and an outlet temperature of about 105°C to about 130°C.

11. The process of claim 9, wherein the Varenicline L-tartrate salt is spray dried at an inlet temperature of about 190°C to about 220°C and an outlet temperature of about 113°C to about 120°C.

12. The process of claim 9, wherein Varenicline L-tartrate salt is spray dried at an inlet temperature of about 213°C to about 220°C and an outlet temperature of about 117°C to about 119°C.

13. The process of any of claims 9 to 12, further comprising preparing the Varenicline L-tartrate subjected to filtration in a process comprising: a) combining a solution of Varenicline base in methanol with L-tartaric acid to obtain Varenicline L-tartrate and b) drying the obtained Varenicline L-tartrate
14. The process of claim 13, wherein the Varenicline L-tartrate obtained is amorphous.
15. The process of claim 13, wherein the obtained Varenicline L-tartrate has a purity of about 100 percent by area HPLC.
16. The process of any of claims 1 to 5, further comprising combining the filtered Varenicline base with methanolic L-tartaric acid to obtain Varenicline L-tartrate.
17. A process for preparing Varenicline L-tartrate crystalline form A, comprising dissolving Varenicline L-tartrate in water, adding the resulting aqueous solution of Varenicline L-tartrate to an anti-solvent, and precipitating Varenicline L-tartrate form A .
18. The process of claim 17, wherein the aqueous solution of Varenicline L-tartrate is added drop-wise into the anti-solvent.
19. The process of claim 17 or claim 18, wherein the aqueous solution of Varenicline L-tartrate is added at a temperature of about 50°C to about 80°C.
20. The process of claim 19, wherein the aqueous solution of Varenicline L-tartrate is added at a temperature of about 70°C.
21. The process of claim 17, wherein the anti-solvent and water have a volume ratio between about 1:15 and about 1:40 (v/v) of water:anti-solvent.
22. The process of claim 17, wherein the anti-solvent and water have a volume ratio between about 1:15 and about 1:35 (v/v) of water:anti-solvent.
23. The process of claim 17, wherein the volume ratio between the anti-solvent and the water is about 1:33 (v/v) of water:anti-solvent.

24. A process for preparing Varenicline L-tartrate crystalline form B, comprising dissolving Varenicline L-tartrate in water, adding an anti-solvent to the resulting aqueous solution of Varenicline L-tartrate, and precipitating Varenicline L-tartrate form B, wherein the water is used in an amount not more than 1.5 percent of the total volume.

25. The process of claim 24, wherein the water is used in an amount not more than 1.3 percent of the total volume.

26. The process of claim 24, wherein the anti-solvent and the water have a volume ratio between about 1:5 to about 1:10 (v/v) of water:anti-solvent.

27. The process of claim 24, wherein the anti-solvent and the water have a volume ratio between about 1:8 to about 1:10 (v/v) of water:anti-solvent.

28. The process of claim 24, wherein the anti-solvent and the water have a volume ratio between about 1:9 (v/v) of water:anti-solvent.

29. The process of any of claims 17 to 28, wherein the anti-solvent is selected from a group consisting of C<sub>1</sub>-C<sub>4</sub> alcohols, tetrahydrofuran, and acetonitrile.

30. The process of any of claims 17 to 28, wherein the anti-solvent is selected from a group consisting of ethanol, isopropanol, tetrahydrofuran, and acetonitrile.

31. The process of any of claims 17 to 28, wherein, the anti-solvent is ethanol.

32. A process for preparing Varenicline L-tartrate crystalline form B, comprising combining Varenicline base, L-tartaric acid, and an ethanol-water solution to precipitate Varenicline L-tartrate crystalline form B.

33. The process of claim 32, wherein the ethanol-water solution has a volume ratio of about 90 percent:10 percent (9:1) to about 98 percent:2 percent (49:1) of ethanol:water (v/v).

34. The process of claim 33, wherein the ethanol-water mixture has a volume ratio of about 95 percent:5 percent (19:1) (v/v).

35. The process of claim 32, wherein the Varenicline base and ethanol-water are combined in a ratio of about 10:1 to about 5:1 of ethanol-water:Varenicline base (v/w).

36. The process of claim 35, wherein the Varenicline base and ethanol-water are combined in a ratio of about 7.5:1 (v/w).

**INTERNATIONAL SEARCH REPORT**

International application No  
PCT/US2009/045478

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. C07D471/08

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/090236 A (PFIZER PROD INC [US]; BUSCH FRANK ROBERT [US]; HAWKINS JOEL MICHAEL [U] 31 August 2006 (2006-08-31) cited in the application example 5	1-16
X	WO 2008/060487 A (PFIZER PROD INC [US]; ALLEN DOUGLAS J M [US]; CASTEEL MELISSA JEAN [US] 22 May 2008 (2008-05-22) cited in the application pages 12-13	1-16
E	WO 2009/065872 A (MEDICHEM SA [ES]; WINTER STEPHEN [ES]; BOTELLA LUIS [ES]; NAJERA CARME) 28 May 2009 (2009-05-28) pages 13,15,18	1-16
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

22 September 2009

Date of mailing of the international search report

29/09/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Duval, Eric

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2009/045478

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 890 927 B2 (BOGLE DAVID E [US] ET AL) 10 May 2005 (2005-05-10) the whole document -----	1, 17, 24, 32

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2009/045478

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the Invitation.
- No protest accompanied the payment of additional search fees.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-16

process for the purification of Varenicline by filtration  
---

2. claims: 17-36

processes for the preparation of Varenicline L-tartrate  
forms A and B  
---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2009/045478

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
WO 2006090236	A	31-08-2006	AT 411994 T	15-11-2008
			AU 2006217616 A1	31-08-2006
			CA 2598533 A1	31-08-2006
			CN 101128462 A	20-02-2008
			EP 1866308 A1	19-12-2007
			ES 2313625 T3	01-03-2009
			JP 2008531540 T	14-08-2008
			KR 20070098942 A	05-10-2007
			US 2008275051 A1	06-11-2008
			<hr style="border-top: 1px dashed black;"/>	
WO 2008060487	A	22-05-2008	AU 2007319951 A1	22-05-2008
			CA 2666327 A1	22-05-2008
			EP 2086977 A2	12-08-2009
<hr style="border-top: 1px dashed black;"/>				
WO 2009065872	A	28-05-2009	NONE	
<hr style="border-top: 1px dashed black;"/>				
US 6890927	B2	10-05-2005	US 2005148591 A1	07-07-2005
			US 2003166701 A1	04-09-2003
<hr style="border-top: 1px dashed black;"/>				